3,5-Dihydroxy-7-[6-hydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 3,5-Dihydroxy-7-[6-hydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
• 英文别名: 3,5-dihydroxy-7-[6-hydroxy-2-methyl-8-(2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
• 化学式: C₂₃H₃₆O₇
• 分子量: 424.5
• InChiKey: TUZYXOIXSAXUGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] PROCESS FOR THE PREPARATION OF 1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (BETA R,DELTA R,1S,2S,6S,8S,8AR)-1-NAPHTHALENEHEPTANOIC ACID, SODIUM SALT.<br/>[FR] PROCEDE PERMETTANT LA PREPARATION DE SEL SODIQUE D'ACIDE 1,2,6,7,8,8A-HEXAHYDRO-BETA, DELTA, 6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (BETA R, DELTA R,1S,2S,6S,8S,8AR)-1-NAPHTHALENEHEPTANOIQUE
  申请人：BIOCON LTD

  公开号：WO2005019155A1

  公开（公告）日：2005-03-03

  A process for the preparation of substantially pure 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (beta R,delta R,1S,2S,6S,8S,8aR)- 1-Naphthaleneheptanoic acid, sodium salt is disclosed.

  揭示了一种制备基本纯的1,2,6,7,8,8a-六氢-β，δ，6-三羟基-2-甲基-8-[(2S)-2-甲基-1-羟基丁酰氧基]-，(β R，δ R，1S，2S，6S，8S，8aR)-1-萘庚酸，钠盐的方法。
• [EN] NOVEL FORMS OF PRAVASTATIN SODIUM<br/>[FR] NOUVELLES FORMES DE PRAVASTATINE SODIQUE
  申请人：BIOGAL GYOGYSZERGYAR

  公开号：WO2001043723A1

  公开（公告）日：2001-06-21

  New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.

  提供了普伐他汀钠的新多态形式。每种新形式是通过从不同的溶剂系统中选择性地结晶获得的，每个溶剂系统都有一个质子性成分，并通过温度控制结晶速率。新的多态形式适用于作为药物剂量形式的活性物质，用于降低血液中的血清胆固醇水平。
• MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT
  申请人：Sankyo Company, Limited

  公开号：EP1782804A1

  公开（公告）日：2007-05-09

  A medicinal composition useful as an excellent preventive or therapeutic agent for diseases relating to immunization. The medicinal composition comprises at least one member selected from the group consisting of HMG-CoA reductase inhibitors and at least one member selected from the group consisting of an amino alcohol derivative represented by the following general formula (I), a pharmacologically acceptable salt of the derivative, and a pharmacologically acceptable ester of the derivative. [In the formula, R1 and R2 are the same or different and each represents a hydrogen, etc.; R3 represents lower alkyl, etc.; R4 represents hydrogen, etc.; R5 represents hydrogen, halogeno, phenyl, etc.; X represents vinylene (CH=CH), methylated nitrogen, etc.; Y represents a single bond, oxygen, sulfur, or carbonyl; Z represents C1-C8 alkylene, etc. ; n is 2 or 3; and the substituents a represent lower alkyl, lower alkoxy, phenyl, etc.]

  一种药物组合物，可作为与免疫有关的疾病的优良预防或治疗剂。该药物组合物包括至少一种选自 HMG-CoA 还原酶抑制剂和至少一种选自以下通式（I）所代表的氨基醇衍生物、该衍生物的药理学上可接受的盐和该衍生物的药理学上可接受的酯组成的组。 [式中，R1 和 R2 相同或不同，各自代表氢等；R3 代表低级烷基等；R4 代表氢等；R5 代表氢、卤素、苯基等；X 代表乙烯基（CH=CH）、甲基化氮等；Y 代表单键、氧、硫或羰基；Z 代表 C1-C8 亚烷基等；n 为 2 或 3；取代基 a 代表低级烷基、低级烷氧基、苯基等。］
• Systems and methods for delivery of materials
  申请人：Landec Corporation

  公开号：EP2502619A2

  公开（公告）日：2012-09-26

  A release composition for agricultural applications which comprises an ECC polymer and a release material associated with the ECC polymer, wherein the release material is a fertilizer, biocide, insecticide or fungicide, and wherein the ECC polymer is defined as a polymer (A) which comprises polymeric molecules having a backbone and comprising at least one moiety which has the formula -b-Cy, wherein the -b-Cy moiety either (a) forms part of a repeating unit of the backbone, the repeating unit having the formula (1) below where Ych is a moiety forming part of the backbone, b is a bond or moiety which links the Cy moiety to Ych, and Cy is a moiety which is associated with other moieties to provide the ECC polymer with crystallinity, or (b) forms part of a terminal unit of the backbone, the terminal unit having the formula (2) below          -Yterm- b-Cy     (2) where Yterm is a moiety at the end of the backbone, and b and Cy are as defined in formula (1); (B) in which at least 50% by weight of the Cy moieties are present in terminal units of formula (2); and (C) which has a crystalline melting temperature, Tp, of at least 0°C and a ΔH of at least 3J/g which results from association of the Cy moieties.

  一种用于农业应用的释放组合物，它包括 ECC 聚合物和与 ECC 聚合物相关的释放材料、 其中释放材料为肥料、杀菌剂、杀虫剂或杀真菌剂，ECC 聚合物定义为聚合物 (A) 由具有骨架的聚合物分子组成，至少包含一个分子式为-b-Cy 的分子，其中-b-Cy 分子可以是 (a) 构成骨架重复单元的一部分，该重复单元具有下式(1) 其中 Ych 是构成骨架一部分的分子，b 是连接 Cy 分子和 Ych 的键或分子，Cy 是与其他分子相连的分子，使 ECC 聚合物具有结晶性、 或 (b) 构成骨架末端单元的一部分，末端单元具有下式 (2) -Yterm- b-Cy (2) 其中 Yterm 是位于骨架末端的分子，b 和 Cy 如式（1）中所定义； (B) 其中至少 50%（按重量计）的 Cy 分子存在于式（2）的末端单元中；以及 (C) 其结晶熔化温度 Tp 至少为 0℃，Cy 分子结合产生的 ΔH 至少为 3J/g。
• Delivery of drugs
  申请人：Landec Corporation

  公开号：EP2500015A1

  公开（公告）日：2012-09-19

  Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.

  药物和结晶侧链聚合物的配方，以提供控释和/或缓释药物制剂。